Here we provide a rationale for applying FOXC2 as a biomarker in prognostication and novel targeted therapy in prostate cancer and lend support to the significance of epithelial–mesenchymal phenotypes in localised and advanced disease. This evidence concerns the gene FOXC2 and prostate cancer.